PRODUCT INFORMATION



LY364947

Item No. 13341

CAS Registry No.: 396129-53-6


Formal Name: 4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]-quinoline Synonyms: HTS 466284, TGF-B RI Kinase Inhibitor

MF: $C_{17}H_{12}N_4$ FW: 272.3 **Purity:** ≥98%

UV/Vis.: λ_{max} : 229, 283 nm A crystalline solid Supplied as:

Storage: -20°C Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



Laboratory Procedures

LY364947 is supplied as a crystalline solid. A stock solution may be made by dissolving the LY364947 in the solvent of choice, which should be purged with an inert gas. LY364947 is soluble in organic solvents such as DMSO and dimethyl formamide (DMF). The solubility of LY364947 in these solvents is approximately 1 and 2 mg/ml, respectively.

LY364947 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, LY364947 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. LY364947 has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Transforming growth factor-β (TGF-β) signals through a cell surface heteromeric complex involving type I (TGF- β RI) and type II (TGF- β RII) receptors. Downstream signal transduction is mediated by the TGF- β RI kinase domain through the phosphorylation of Smad proteins. LY-364947 is a selective inhibitor of TGF-β RI (TGFR-I, T β R-I, ALK-5), with an IC₅₀ value of 59 nM.¹ LY-364947 less effectively inhibits TGF- β RII $(IC_{50} = 400 \text{ nM})$, p38 MAPK $(IC_{50} = 740 \text{ nM})$, and mixed-lineage kinase 7 (MLK7; $IC_{50} = 1,400 \text{ nM})$. 1t inhibits TGF- β -induced cell growth (IC₅₀ = 89 nM) in NIH 3T3 mouse fibroblasts and TGF- β -directed Smad phosphorylation, synthesis of fibronectin, PAI-1 and uPA protein, and matrigel invasion in MDA-MB-231 cells.1,3

References

- 1. Sawyer, J.S., Anderson, B.D., Beight, D.W., et al. Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain. J. Med. Chem 46(19), 3953-3956 (2003).
- 2. Li, H., Wang, Y., Heap, C.R., et al. Dihydropyrrolopyrazole transforming growth factor-β type I receptor kinase domain inhibitors: A novel benzimidazole series with selectivity versus transforming growth factor-β type II receptor kinase and mixed lineage kinase-7. J. Med. Chem 49(6), 2138-2142 (2006).
- 3. Shiou, S.-R., Datta, P.K., Dhawan, P., et al. Smad4-dependent regulation of urokinase plasminogen activator secretion and RNA stability associated with invasiveness by autocrine and paracrine transforming growth factor. J. Biol. Chem. 281(45), 33971-33981 (2006).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information Buyer agrees to purchase the mater can be found on our website.

Copyright Cayman Chemical Company, 03/19/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM